Magenta is focused on improving the patient experience in transplant medicine, with the goal of bringing this lifesaving procedure to more patients. Over the past 50 years, stem cell transplantation has been used in more than 1M patients worldwide. It is currently the only treatment with the potential to cure some of the most devastating hematologic cancers and autoimmune diseases. Despite the increased use and clinical advancements over the past several decades, stem cell transplant remains a high-risk last-resort therapeutic option due to the toxicity and potential long-term side effects.

iCell Gene Therapeutics, Inc. operates as a a clinical-stage biotechnology company. The firm develops first-in-class chimeric antigen receptor engineered cells. The company was founded by Yupo Ma and is headquartered in Stony Brook, NY.

The Eli and Edythe L. Broad Institute of MIT and Harvard (/ˈbroʊd/), often referred to as the Broad Institute, is a biomedical and genomic research center located in Cambridge, Massachusetts, United States. The institute is independently governed and supported as a 501(c)(3) nonprofit research organization under the name Broad Institute Inc., and is partners with Massachusetts Institute of Technology, Harvard University, and the five Harvard teaching hospitals.

Symphogen is a biotechnology company located in Copenhagen, Denmark that develops protein drugs based on recombinant monoclonal antibody mixtures. These drugs are different from the polyclonal antibodies, as each antibody in the mixture is produced from one carefully selected clone. Their three main areas of therapeutic research are immunoglobulin replacement, cancer, and infectious diseases. The company was founded in 2000 and has patents on a drug discovery platform called Symplex and a drug manufacturing platform called Sympress. Currently, ten drugs are being developed with rozrolimupab (Sym001) being the lead product.

Nanjing IASO Biotherapeutics Co., Ltd. is a Chinese company located in Nanjing. The firm engages in research, development and commercialization of cell therapies in the field of oncology. It was founded in 2017. Wen Wang has been the CEO since 2020.

Guangzhou Kingmed Center For Clinical Laboratory Co., Ltd. provides clinical and laboratory testing services. It offers clinical trials, medical examination, food and hygiene testing, physical examination, scientific research services, and quality management. The company was founded by YaoMing Liang in 1994 and is headquartered in Guangzhou, China.

Fuzhou Maixin Biotech Co., Ltd. (doing business as MXB Biotechnologies), part of Beijing Strong Biotechnologies, Inc., is a Chinese company located in Fuzhou. The firm engages in production, research & development and sales and focus on tissue-based diagnostics specifically IHC antibodies, reagents and the automation of IHC and ISH. It was founded in 1993. Xiao Ya Wang is the current CEO of the firm. Fuzhou Maixin Biotech Co. Ltd. acquired Fuzhou Maixin Biotech Co., Ltd. on September 30, 2020 for $255.21 million.

Wuxi Aorui Dongyuan Biotechnology Co., Ltd., established on 2010-10-13, Business scope includes biological genetic products,biomedicine,Biomaterials Research,to develop,technology transfer,technical consulting;Pharmaceutical Intermediates,Comprehensive agent for experiment,Manufacture and sales of medical devices(Items requiring a permit,Operate with a valid license);Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export);Biological product,biologics,Manufacture and sale of specific immunoglobulin products.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Xencor provides protein engineering technology platforms in the biotechnology industry. Its products include antibody therapeutics, such as XmAb2513 for the treatment of relapsed Hodgkin’s lymphoma and anaplastic large cell lymphoma; XmAb5574, a humanized monoclonal antibody that targets the antigen CD19 for the treatment of B cell malignancies; XmAb5592 for the treatment of myeloma; and XmAb5871 and XmAb7195, which are humanized monoclonal antibodies for the treatment of asthma and allergy. The company’s products also include XPro protein therapeutics, such as XPro1595, a dominant-negative inhibitor for the treatment of multiple animal models of autoimmune and neuroinflammatory diseases.

Heidelberg Pharma Research GmbH, part of Heidelberg Pharma AG, is a company headquartered in Ladenburg, Germany, that engages in researching biotechnology. The firm was founded in 2011. Jan Schmidt-Brand is the CEO, in this role since 2004.

F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Part of Jiangsu Xiansheng Medical Diagnosis Co. Ltd., Jiangsu Simcere Pharmaceutical Co., Ltd. is a Chinese company located in Nanjing that manufactures and sells pharmaceutical products. The firm was founded in 1995.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

Shanghai Reindeer Biotechnology Co., Ltd., established on 2020-11-25, Business scope includes general items:Engaged in technology development in the field of biotechnology,technical consulting,Technical Services,technology transfer;Medical Research and Experimental Development;Import and export,Technology Import and Export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Korea Research Institute of Bioscience and Biotechnology (KRIBB) is a government research institute in Daejeon, South Korea. It is dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as drug discovery, novel biomaterials, integrated biotechnology and bioinformation.